Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Assets

CYB003

Cybin

Molecule class
deuterated psilocin analogue (company description)
Mechanism
Not independently verified.
Phase
Phase 3 recruiting
Indication
major depressive disorder
Sponsor geography
IE
Next catalyst
None recorded.
IP status
Not checked. Recorded as unchecked rather than left blank.

clinicaltrials.govregistryverified 2026-08-24

Registered trials

  • NCT06605105ClinicalTrials.gov

    PHASE3 · Major Depressive Disorder · ENROLLING_BY_INVITATION · Australia, United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT06793397ClinicalTrials.gov

    PHASE3 · Major Depressive Disorder (MDD);Depression in Adults;Depression - Major Depressive Disorder;Depression Disorders;Depression Disorder;Depression · RECRUITING · Australia, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • 2024-516805-22-00CTIS

    Therapeutic confirmatory (Phase III) · Major Depressive Disorder · Authorised · Czechia, Germany, Greece, Ireland, Poland

    euclinicaltrials.euctis registryverified 2026-08-31

In the briefing

Issues tagged CYBIN, the owner of this asset.